# The Johns Hopkins Translational Science Team for the ET-CTN

> **NIH NIH UM1** · JOHNS HOPKINS UNIVERSITY · 2021 · $99,789

## Abstract

This application is being submitted to request additional funds for Affiliated Organizations (AO) to an ETCTN
UM1 Lead Academic Organization (LAO). With the evolution of the Experimental Therapeutics Clinical Trials
Network (ETCTN), the Johns Hopkins Translational Science Team (JHTST) expanded in 2016 by bringing 5
(now 8 with the 2020 administrative supplement) AO under our LAO with the goal to enhance and accelerate
our collective contribution to the drug development efforts of the NCI. We have organized a comprehensive
and cohesive infrastructure that can conduct high-quality clinical trials evaluating novel anticancer agents, in
combinations, in molecularly selected patient populations, or rare tumor sites. Our infrastructure stems from
the need to be clinically efficient, regulatory compliant and scientifically rigorous in our approach as we
collaborate as network members within the ETCTN. With the submission of this administrative supplement, our
infrastructure will now consist of nine experienced NCI-designated Cancer Centers: Johns Hopkins Sidney
Kimmel Comprehensive Cancer Center, Emory Winship Cancer Institute, Georgetown Lombardi
Comprehensive Cancer Center, Sidney Kimmel Cancer Center at Thomas Jefferson University, Memorial
Sloan Kettering Cancer Center, University of Virginia Cancer Center, University of Wisconsin Carbone Cancer
Center, University of Colorado Comprehensive Cancer Center, and The University of Maryland Greenebaum
Cancer Center. This collection of Centers brings together many unique discovery strengths, diverse patient
volumes, and locations both urban and rural. We will focus on 4 Specific Aims: Aim 1- To lead and maintain a
clinical trial consortium that will support cancer clinical trials from Phase 1 initiation through proof-of-activity
and foster seamless Phase 2 clinical development of NCI CTEP IND agents; Aim 2- To actively participate and
engage disease-focused clinical investigators in the ETCTN by promoting accrual to a range of ETCTN studies
led by other LAO/AO members; Aim 3- To incorporate and implement innovative correlative and biological
laboratory studies in the context of or as eligibility for participation in early phase clinical studies that enhance
our understanding of determinants of toxicity and response that will be used for further definitive practice-
changing clinical trial evaluation; and Aim 4- To train the next generation of investigators in drug development.
With 9 Centers within our Consortium, we anticipate no problem in meeting the grant metrics of 100 accruals
per year, submitting 8 LOI concepts to have 1 new studies approved each year, functioning as a network by
having Disease-Focused Clinical Investigators champion ETCTN studies at each Site across disease sites,
and to provide opportunities to engage and train early career investigators in drug development. We anticipate
that our contributions within the ETCTN will impact the clinical care of cancer patients.

## Key facts

- **NIH application ID:** 10393294
- **Project number:** 3UM1CA186691-06S1
- **Recipient organization:** JOHNS HOPKINS UNIVERSITY
- **Principal Investigator:** Michael A Carducci
- **Activity code:** UM1 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $99,789
- **Award type:** 3
- **Project period:** 2020-05-01 → 2023-02-28

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10393294

## Citation

> US National Institutes of Health, RePORTER application 10393294, The Johns Hopkins Translational Science Team for the ET-CTN (3UM1CA186691-06S1). Retrieved via AI Analytics 2026-05-21 from https://api.ai-analytics.org/grant/nih/10393294. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*